Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes

Abstract

This meta-analysis provides a convincing signal that SGLT-2i have a salutary effect on NAFLD in type 2 diabetes (T2D), probably driven by an improvement of glycemia and body weight, which in turn attenuates hepatic inflammation and hepatic fat accumulation.